Pharmaceuticals

Multiple Sclerosis Drugs Market Forecast 2026–2030 Presenting Long-Term Industry Insights

May 1, 2026May 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Are The Market Size Estimates For The Multiple Sclerosis Drugs Market In 2026 And 2030?

The multiple sclerosis drugs market size has seen substantial growth over the past few years. It is anticipated to expand from $33.46 billion in 2025 to $37.67 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 12.6%. This historical development can be ascribed to a number of factors, including the limited availability of MS therapies, the increasing prevalence of multiple sclerosis, heightened awareness among patients and physicians, a reliance on interferon-based therapies, and the expansion of hospital and retail pharmacy networks.

The multiple sclerosis drugs market is anticipated to experience substantial expansion in the coming years. This market is projected to reach $61.43 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 13.0%. The upward trajectory during the forecast period is attributable to the development of novel monoclonal antibodies, the increasing availability of oral disease-modifying therapies, the incorporation of personalized medicine into MS treatment, heightened investment in research and development for emerging therapies, and the growing utilization of digital health monitoring and telemedicine platforms. Furthermore, prominent trends expected within this period include a rising adoption of disease-modifying therapies for multiple sclerosis, an expansion in personalized and targeted MS treatment approaches, the broadening of hospital and retail pharmacy distribution channels, an increasing preference for oral and parenteral routes of administration, and the emergence of new immunomodulators, immunosuppressants, and monoclonal antibodies.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2817&type=smp

What Primary Drivers Are Shaping The Multiple Sclerosis Drugs Market?

Support from both governmental and non-governmental entities contributes to the expansion of the multiple sclerosis drugs market. These organizations, both government and non-government, finance various initiatives and programs designed to improve the quality of life for individuals living with multiple sclerosis (MS). A notable example involves the government of Alberta, collaborating with the Department of Economic Development, Trade, and Tourism in Canada, which allocated $1 million to the Canadian Prospective Cohort Study to Understand Progression in Multiple Sclerosis (CanProCo). This investment aimed to bolster research and innovative approaches, thereby improving the comprehension and treatment of MS disease. CanProCo represents a collaborative endeavor, unifying the work of approximately 50 MS researchers from diverse fields throughout Canada. Additional funding for this initiative came from Canada Brain Research, Biogen Canada, the MS Society of Canada, and Hoffmann-La Roche Limited (Roche Canada), collectively accumulating $10 million. Such substantial financial backing from government and non-government bodies significantly propels the expansion of the multiple sclerosis drugs market.

How Is The Multiple Sclerosis Drugs Market Organized By Segment Classification?

The multiple sclerosis drugs market covered in this report is segmented –

1) By Drug Class: Immunomodulators, Immunosuppressants, Interferons, Other Drug Classes

2) By Distribution Channels: Hospital Pharmacy, Retail Pharmacy, Online Stores

3) By Route Of Administration: Oral Drugs, Parenteral Drugs

Subsegments:

1) By Immunomodulators: Glatiramer Acetate, Fingolimod, Teriflunomide, Dimethyl Fumarate

2) By Immunosuppressants: Natalizumab, Alemtuzumab, Ocrelizumab

3) By Interferons: Interferon Beta-1a, Interferon Beta-1b

4) By Other Drug Classes: Sphingosine 1-Phosphate Receptor Modulators, Monoclonal Antibodies, Other Emerging Therapies

Which Trends Are Impacting The Progress Of The Multiple Sclerosis Drugs Market?

Leading companies in the multiple sclerosis drugs market are dedicated to developing novel solutions to enhance treatment effectiveness, improve patients’ quality of life, and address the varied needs of individuals living with multiple sclerosis. These innovative solutions refer to fresh and creative approaches, products, or technologies designed to effectively resolve specific challenges or problems. For example, in September 2024, Genentech, a US-based biotechnology company, announced that the U.S. Food and Drug Administration (FDA) had approved Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). Ocrevus Zunovo is notably the first and only subcutaneous injection, administered by healthcare professionals, that is given twice a year and takes approximately 10 minutes, offering individuals with MS additional treatment options.

Who Are The Industry Participants Involved In The Multiple Sclerosis Drugs Market?

Major companies operating in the multiple sclerosis drugs market are Biogen Inc., Novartis International AG, F. Hoffmann-La Roche Ltd., Bayer HealthCare LLC, Merck & Co. Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Acorda Therapeutics Inc., EMD Serono Inc., AbbVie Inc., Bayer Schering Pharma AG, Bristol-Myers Squibb Company, Johnson & Johnson, Mitsubishi Tanabe Pharma Corporation, Opexa Therapeutics Inc., Receptos Inc., Synthon Pharmaceuticals Inc., TG Therapeutics Inc., Alkermes plc, Amgen Inc., Atara Biotherapeutics Inc., Celgene Corporation, Genzyme Corporation

Get The Full Multiple Sclerosis Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/multiple-sclerosis-drugs-global-market-report

Which Region Represents The Largest Share Of The Multiple Sclerosis Drugs Market?

North America was the largest region in the global multiple sclerosis drug market in 2025. The Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the multiple sclerosis drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Multiple Sclerosis Drugs Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/multiple-sclerosis-drugs-global-market-report

Browse Through More Reports Similar to the Global Multiple Sclerosis Drugs Market 2026, By The Business Research Company

Musculoskeletal Disorder Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/musculoskeletal-disorder-drugs-global-market-report

Macular Degeneration Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/macular-degeneration-treatment-global-market-report

Central Nervous System Drug Market Report 2026

https://www.thebusinessresearchcompany.com/report/central-nervous-system-drug-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795